Phase II study of SKL 11197 (SK Biopharmaceuticals) for Diabetic Peripheral Neuropathy initiated in US

SK Biopharmaceuticals has initiated a Phase II trial for US patients suffering with Diabetic Peripheral Neuropathy using their investigational drug SKL11197. Unlike many other drugs currently marketed for the treatment of Neuropathic Pain that were originally developed for the treatment of epilepsy or depression, SKL11197 has been developed solely for the treatment of pain. SKL11197 has already been proven safe in Phase I studies - at the highest tested dose level of 1,350 mg, the drug did not show any significant signs of drowsiness or sedation. If the Phase II clinical trials and coming Phase III trials are successful, it is expected that SKL11197 would be launched in 2018.